LEDDEGIGT – - Sundhedsstyrelsen

Litteratur
16 Kim JM, Weisman MH.
When does rheumatoid
arthritis begin and
why do we need to
know? Arthritis Rheum
2000; 43(3):473-484.
17 Lindqvist E, Eberhardt K.
Mortality in rheumatoid
arthritis patients
with disease onset in
the 1980s. Ann Rheum
Dis 1999; 58(1):11-14.
18 Kroot EJ, van Leeuwen
MA, van Rijswijk MH,
Prevoo ML, ’t Hof MA,
van de Putte LB et al.
No increased mortality
in patients with
rheumatoid arthritis:
up to 10 years of follow
up from disease
onset. Ann Rheum Dis
2000; 59(12):954-958.
19 Symmons DP, Jones
MA, Scott DL, Prior P.
Longterm mortality
outcome in patients
with rheumatoid
arthritis: early presenters
continue to do
well. J Rheumatol 1998;
25(6):1072-1077.
20 Albers JM, Paimela L,
Kurki P, Eberhardt KB,
Emery P, ’t Hof MA et
al.
Treatment strategy,
disease activity, and
outcome in four cohorts
of patients with
early rheumatoid
arthritis. Ann Rheum
Dis 2001; 60(5):453-
458.
21 Stenger AA, van
Leeuwen MA,
Houtman PM, Bruyn
GA, Speerstra F,
Barendsen BC et al.
Early effective suppression
of inflammation
in rheumatoid
arthritis reduces radiographic
progression.
Br J Rheumatol 1998;
37(11):1157-1163.
22 Munro R, Hampson R,
McEntegart A,
Thomson EA, Madhok
R, Capell H.
Improved functional
outcome in patients
with early rheumatoid
arthritis treated with
intramuscular gold: results
of a five year
prospective study. Ann
Rheum Dis 1998;
57(2):88-93.
23 Nell VPK, Machold KP,
Eberl G, Uffmann M,
Stamm T, Smolen JS.
Benefit of very early
referral and therapy
with disease modifying
antirheumatic drugs in
patients with early
rheumatoid arthritis.
Ann Rheum Dis 2002;
61(suppl. 1):37.
24 Wiles NJ, Lunt M,
Barrett EM, Bukhari M,
Silman AJ, Symmons
DP et al.
Reduced disability at
five years with early
treatment of inflammatory
polyarthritis:
results from a large
observational cohort,
using propensity models
to adjust for disease
severity. Arthritis
Rheum 2001;
44(5):1033-1042.
25 Mottonen T,
Hannonen P, Korpela
M, Nissila M,
Kautiainen H, Ilonen J
et al.
Delay to institution of
therapy and induction
of remission using single-drug
or combination-disease-modifying
antirheumatic drug
therapy in early
rheumatoid arthritis.
Arthritis Rheum 2002;
46(4):894-898.
26 Wolfe F.
The natural history of
rheumatoid arthritis.
Journal of
Rheumatology 1996;
23(Suppl. 44):13-22.
27 van der Heide A,
Jacobs JW, Bijlsma JW,
Heurkens AH, Booma-
Frankfort C, van der
Veen MJ et al.
The effectiveness of
early treatment with
“second-line” antirheumatic
drugs.
A randomized,
controlled trial. Ann
Intern Med 1996;
124(8):699-707.
28 Egsmose C, Lund B,
Borg G, Pettersson H,
Berg E, Brodin U et al.
Patients with rheumatoid
arthritis benefit
from early 2nd line
therapy: 5 year followup
of a prospective
double blind
placebo controlled
study. J Rheumatol
1995; 22(12):2208-2213.
29 Tsakonas E, Fitzgerald
AA, Fitzcharles MA,
Cividino A, Thorne JC,
M’Seffar A et al.
Consequences of delayed
therapy with
secondline agents in
rheumatoid arthritis: a 3
year followup on the
hydroxychloroquine in
early rheumatoid
arthritis (HERA) study. J
Rheumatol 2000;
27(3):623-629.
30 Miyagi K, Azuma T,
Naitoh A, Sakaida H,
Sakata M, Nakagawa T
et al.
A 15-year follow-up
study on the outcome
in patients with early
rheumatoid arthritis.
Japanese J Rhe-matol
1998; 8(2):117-129.
31 Harrison BJ, Symmons
DP, Barrett EM, Silman
AJ.
The performance of the
1987 ARA classification
criteria for rheumatoid
arthritis in a population
based cohort of patients
with early inflammatory
polyarthritis. American
Rheumatism Association.
J Rheumatol
1998; 25(12):2324-2330.
32 Arnett FC, Edworthy
SM, Bloch DA, McShane
DJ, Fries JF, Cooper NS
et al.
The American
Rheumatism
Association 1987 revised
criteria for the
classification of
rheumatoid arthritis.
Arthritis Rheum 1988;
31(3):315-324.
33 Guidelines for the management
of rheumatoid
arthritis.
American College of
Rheumatology Ad Hoc
Committee on Clinical
Guidelines. Arthritis
Rheum 1996; 39(5):713-
722.
34 Fries JF.
Criteria for Rheumatic
Disease. Different types
and different functions.
Arthritis and Rheumatism
1994; 4:454-462.
35 Hülsemann JL, Zeidler H.
Diagnostic evaluation
of classification criteria
for rheumatoid arthritis
and reactive arthritis in
an early synovitis outpatient
clinic. Ann
Rheum Dis 1999;
58(5):278-280.
36 van der Horst-Bruinsma
IE, Speyer I, Visser H,
Breedveld FC, Hazes JM.
Diagnosis and course of
early-onset arthritis: results
of a special early
arthritis clinic compared
to routine patient
care. Br J Rheumatol
1998; 37(10):1084-1088.
37 Hernandez-Cruz B,
Cardiel MH.
Intra-observer reliability
of commonly used
outcome measures in
rheumatoid arthritis.
Clin Exp Rheumatol
1998; 16(4):459-462.
38 Van Riel PLCM, van
Gestel AM, Scott DL.
EULAR Handbook of
Clinical Assessments in
Rheumatoid Arthritis.
Vienna: EULAR, 2000.
39 Kraan MC, Versendaal H,
Jonker M, Bresnihan B,
Post WJ, Hart BA et al.
Asymptomatic synovitis
precedes clinically
manifest arthritis.
Arthritis Rheum 1998;
41(8):1481-1488.
40 Wolfe F, Ross K, Hawley
DJ, Roberts FK, Cathey
MA.
The prognosis of
rheumatoid arthritis
and undifferentiated
polyarthritis syndrome
in the clinic: a study of
1141 patients. J
Rheumatol 1993;
20(12):2005-2009.
41 Green M, Marzo-Ortega
H, McGonagle D,
Wakefield R, Proudman
S, Conaghan P et al.
Persistence of mild, early
inflammatory arthritis:
the importance of disease
duration, rheumatoid
factor, and the shared
epitope. Arthritis Rheum
1999; 42(10):2184-2188.
42 Mottonen T, Paimela L,
Leirisalo-Repo M,
Kautiainen H, Ilonen J,
Hannonen P.
Only high disease
activity and positive
rheumatoid factor indicate
poor prognosis in
patients with early
rheumatoid arthritis
treated with “sawtooth”
strategy. Ann Rheum
Dis 1998; 57(9):533-539.
43 McQueen FM. Magnetic
resonance imaging in
early inflammatory
arthritis: what is its
role? Rheumatology
(Oxford) 2000;
39(7):700-706.
62 LEDDEGIGT – medicinsk teknologivurdering af diagnostik og behandling
LEDDEGIGT – medicinsk teknologivurdering af diagnostik og behandling 63